REG - capAI PLC - Incorporation of capMedical Inc and Other Updates

capAIAnnouncement

07/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251007:nRSG2855Ca&default-theme=true

RNS Number : 2855C  capAI PLC  07 October 2025

THIS ANNOUNCEMENT ("ANNOUNCEMENT") AND THE INFORMATION CONTAINED HEREIN IS
RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR
INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, ITS
STATES, TERRITORIES AND POSSESSIONS ("UNITED STATES" OR "US"), AUSTRALIA,
CANADA, JAPAN, SINGAPORE, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER
JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE
PROHIBITED BY ANY APPLICABLE LAW.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
REGULATION 2014/596/EU, WHICH IS PART OF THE DOMESTIC LAW OF THE UNITED
KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND ("UK") PURSUANT TO THE MARKET
ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE
PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK
MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

7 October 2025

capAI plc

(the "Company" and, together with its subsidiaries and subsidiary
undertakings, the "Group" or "capAI")

 

Incorporation of capMedical Inc, Renaming of UK Subsidiaries

and Submission of Prospectus

 

capAI (LSE: CPAI) is pleased to announce the incorporation of capMedical Inc,
a wholly owned US subsidiary established to advance the Group's artificial
intelligence ("AI")-driven medical and longevity initiatives in the United
States.

 

The incorporation of capMedical Inc in the State of Delaware marks a new
operational milestone as the Company initiates its capMedical division, which
forms part of capAI's broader Identify, Incubate and Invent strategy.

 

This new structure mirrors the model established for capMedia Inc, the Group's
US subsidiary supporting its media activities, and represents a further step
in the structured build-out of the Company's transatlantic operating
framework.

 

Together, these entities provide the foundation for collaboration,
development, and future commercialisation of AI applications in media,
medicine, and longevity.

 

capAI continues to assess opportunities consistent with its AI in medicine and
longevity strategy. Any such initiatives will be pursued selectively and
responsibly, with a focus on long-term value creation.

 

The Company intends to apply for an operational licence for capMedical Inc to
conduct business in the State of California at the appropriate time. Once
licensed, capMedical Inc will serve as the Group's principal US operating
vehicle for medical, scientific, and longevity-focused initiatives,
collaborations, and technology partnerships. Further US state registrations
will be pursued as required.

 

Renaming of UK subsidiaries

 

The Company has also renamed its two UK subsidiaries: capMedia (UK) Ltd and
capMedical (UK) Ltd. Any UK-based activities within these respective divisions
will be undertaken through these vehicles.

 

Prospectus Submission

 

The Company also confirms that it has submitted a Prospectus to the Financial
Conduct Authority and that the review process is well underway.

 

The Prospectus is designed to address current headroom restrictions and
establish a framework that provides the Company with greater operational
flexibility to support its strategic objectives. The Company shall make a
further statement regarding the Prospectus as and when appropriate.

 

The Board remains committed to building long-term shareholder value through
the disciplined execution of its AI-led operating strategy. capAI's approach
continues to emphasise high efficiency, capital discipline, and responsible
growth, with both Professor Ronjon Nag and Richard Edwards holding substantial
shareholdings that align the interests of the Board with those of all
shareholders.

 

For the purposes of UK MAR, the person responsible for arranging release of
this Announcement on behalf of capAI is Richard Edwards, Executive Chairman.

 

 

Enquiries

 

Company:

capAI plc hello@capaiplc.com

 

Broker Enquiries:

Peterhouse Capital Limited Tel: +44 (0) 207 469 0930

 

Important legal Information

 

The information contained in this Announcement is for background purposes only
and does not purport to be full or complete, nor does this Announcement
constitute or form part of any invitation or inducement to engage in
investment activity. No reliance may be placed by any person for any purpose
on the information contained in this Announcement or its accuracy, fairness or
completeness. The contents of this Announcement are not to be construed as
legal, financial or tax advice.

 

This Announcement does not constitute or form part of any offer or invitation
to sell or issue, or any solicitation of any offer to purchase or subscribe
for, any securities, nor shall it (or any part of it), or the fact of its
distribution, form the basis of, or be relied on in connection with, any
contract therefor.

 

This Announcement may include forward-looking statements, which are based on
current expectations and projections about future events, including about the
Group's operations, strategy, financial performance, development milestones,
and the future prospects of its business divisions, including capMedia Inc,
capMedical Inc, capMedia (UK) Ltd and capMedical (UK) Ltd. These statements
may include, without limitation, any statements preceded by, followed by or
including words such as "target", "believe", "expect", "aim", "intend", "may",
"anticipate", "estimate", "plan", "project", "will", "can have", "likely",
"should", "would", "could" and any other words and terms of similar meaning or
the negative thereof.

 

Forward-looking statements are based on current expectations and are subject
to various risks and uncertainties that could cause actual outcomes to differ
materially. These risks include, but are not limited to: successful execution
of definitive agreements; regulatory approvals; development timelines; market
acceptance; technological shifts; and broader economic conditions. No
representation or warranty is made or will be made that any forward-looking
statement will come to pass, and no assurance can be given that any
forward-looking statement will prove accurate. Except as required by law,
capAI undertakes no obligation to revise or update any forward-looking
statement. The forward-looking statements in this Announcement speak only as
at the date of this Announcement.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDEAAEKEDSSFAA